80wk Uptrend — rising+above (sma 23.75 vs px 31.45)
200wk Uptrend — rising+above (sma 19.02 vs px 31.45)
Short Squeeze Setup — velZ +0.74 · age 14w×1.00 · 6.88%
Seasonal Tailwind — august med 16.6% (mag 3/3) · posClose 63.16% (rel 2/3) · n19 ×0.75 = 7
Founder-Led — founder/CEO led
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor th… Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: November 8, 2006
Headquarters: 355 Alhambra Circle, Coral Gables, FL, United States, 33134
Founder-Led: Yes — Patrick J. McEnany (Co-Founder & Non-Executive Chairman)
Key Metrics
Current Price
$31.47
Market Cap
$3.85B
Float
115.6M
Shares Outstanding
122.4M
P/E (Forward)
12.95
P/E (TTM)
18.19
Price/Sales (TTM)
6.45
vs. Analyst Target
+0.6% to analyst PT
Profit Margin
37.08%
Operating Margin (TTM)
49.02%
Revenue (TTM)
$597M
Earnings Growth (YoY)
11.10%
Dividend Rate
None
Analyst Target Price
$31.67 (7 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
$119M
$75.0M
$102M
$42.2M
2021
$141M
$39.5M
$119M
$52.6M
2022
$214M
$83.1M
$180M
$103M
2023
$398M
$71.4M
$346M
$127M
2024
$492M
$164M
$423M
$254M
2025
$589M
$214M
$502M
$321M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Jun 2025
$147M
$52.1M
Sep 2025
$148M
$52.8M
Dec 2025
$153M
$52.7M
Mar 2026
$149M
$63.7M
Ownership & Float
Insider Ownership
5.6%
Institutional Ownership
89.7%
Short Float
6.9%
% of All Funds Holding
4.29%
Number of Funds Holding
353
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$31.32
Near-term / short-term trend
Weekly
40-Week SMA
$25.53
Medium-term trend
Weekly
80-Week SMA
$23.88
Cyclical trend (business cycle)
Weekly
200-Week SMA
$19.11
Secular trend (multi-year)
Monthly
10-Month SMA
$26.24
Near-term monthly trend
Monthly
20-Month SMA
$24.28
Medium-term monthly trend
Monthly
40-Month SMA
$20.10
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$28.20
support
1.97x
1 months ago
$24.60
support
1.31x
2 months ago
Historical Earnings Reactions (76 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
0.70%
0.00%
40.79%
12.92%
-8.22%
1 Day
-0.37%
-0.65%
39.47%
23.87%
-21.60%
1 Week
2.71%
0.60%
52.63%
64.29%
-32.94%
2 Weeks
6.72%
4.81%
63.16%
122.50%
-58.57%
1 Month
9.17%
6.46%
61.33%
152.38%
-66.67%
Next earnings: August 5, 2026 (24 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
5.6%
60.0%
20
Feb
-1.2%
65.0%
20
Mar
10.0%
65.0%
20
Apr
4.0%
45.0%
20
May
-2.3%
60.0%
20
Jun
3.7%
55.0%
20
Jul
11.1%
57.9%
19
Aug
22.1%
63.2%
19
Sep
-2.8%
36.8%
19
Oct
-4.9%
42.1%
19
Nov
1.6%
57.9%
19
Dec
-3.2%
30.0%
20
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
0.75%
47.6%
927
Tuesday
0.09%
45.2%
1015
Wednesday
0.08%
44.3%
1014
Thursday
-0.03%
45.3%
995
Friday
0.14%
46.3%
990
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 89.7%
Insider Transactions — Smart Summary
Total insider ownership: 5.6%
Founder-led management: Patrick J. McEnany (Co-Founder & Non-Executive Chairman)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Catalyst Pharmaceuticals Inc
(CPRX) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.